ES2217956B1 - Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. - Google Patents

Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Info

Publication number
ES2217956B1
ES2217956B1 ES200300172A ES200300172A ES2217956B1 ES 2217956 B1 ES2217956 B1 ES 2217956B1 ES 200300172 A ES200300172 A ES 200300172A ES 200300172 A ES200300172 A ES 200300172A ES 2217956 B1 ES2217956 B1 ES 2217956B1
Authority
ES
Spain
Prior art keywords
pyrimidin
carbonitrile
methyl
amino
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200300172A
Other languages
English (en)
Spanish (es)
Other versions
ES2217956A1 (es
Inventor
Emma Terricabras Belart
Victor Manuel Segarra Matamoros
Julio Alvarez-Builla Gomez
Juan Jose Vaquero Lopez
Jose Miguel Minguez Ortega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200300172A priority Critical patent/ES2217956B1/es
Application filed by Almirall Prodesfarma SA filed Critical Almirall Prodesfarma SA
Priority to EP04704579A priority patent/EP1590352B1/en
Priority to AT04704579T priority patent/ATE365742T1/de
Priority to CN200480007362A priority patent/CN100582112C/zh
Priority to PCT/EP2004/000584 priority patent/WO2004065391A1/en
Priority to DE602004007239T priority patent/DE602004007239T2/de
Priority to JP2006500010A priority patent/JP2006515604A/ja
Priority to ES04704579T priority patent/ES2289475T3/es
Priority to US10/542,940 priority patent/US7662814B2/en
Publication of ES2217956A1 publication Critical patent/ES2217956A1/es
Application granted granted Critical
Publication of ES2217956B1 publication Critical patent/ES2217956B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES200300172A 2003-01-23 2003-01-23 Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. Expired - Fee Related ES2217956B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES200300172A ES2217956B1 (es) 2003-01-23 2003-01-23 Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
AT04704579T ATE365742T1 (de) 2003-01-23 2004-01-23 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
CN200480007362A CN100582112C (zh) 2003-01-23 2004-01-23 用作PDE7抑制剂的4-氨基噻吩并[2,3-d]嘧啶-6-甲腈衍生物
PCT/EP2004/000584 WO2004065391A1 (en) 2003-01-23 2004-01-23 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS
EP04704579A EP1590352B1 (en) 2003-01-23 2004-01-23 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS
DE602004007239T DE602004007239T2 (de) 2003-01-23 2004-01-23 4-AMINOTHIENO[2,3-d] PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7-INHIBITOREN
JP2006500010A JP2006515604A (ja) 2003-01-23 2004-01-23 Ｐｄｅ７阻害剤としての４−アミノチエノ［２，３−ｄ］ピリミジン−６−カルボニトリル誘導体
ES04704579T ES2289475T3 (es) 2003-01-23 2004-01-23 Derivados de l-aminotieno(2,3-d)pirimidina-6-carbonitrilo como inhibidores de pde7.
US10/542,940 US7662814B2 (en) 2003-01-23 2004-01-23 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200300172A ES2217956B1 (es) 2003-01-23 2003-01-23 Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Publications (2)

Publication Number Publication Date
ES2217956A1 ES2217956A1 (es) 2004-11-01
ES2217956B1 true ES2217956B1 (es) 2006-04-01

Family

ID=32749101

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200300172A Expired - Fee Related ES2217956B1 (es) 2003-01-23 2003-01-23 Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES04704579T Expired - Lifetime ES2289475T3 (es) 2003-01-23 2004-01-23 Derivados de l-aminotieno(2,3-d)pirimidina-6-carbonitrilo como inhibidores de pde7.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04704579T Expired - Lifetime ES2289475T3 (es) 2003-01-23 2004-01-23 Derivados de l-aminotieno(2,3-d)pirimidina-6-carbonitrilo como inhibidores de pde7.

Country Status (8)

Country Link
US (1) US7662814B2 (cg-RX-API-DMAC7.html)
EP (1) EP1590352B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006515604A (cg-RX-API-DMAC7.html)
CN (1) CN100582112C (cg-RX-API-DMAC7.html)
AT (1) ATE365742T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004007239T2 (cg-RX-API-DMAC7.html)
ES (2) ES2217956B1 (cg-RX-API-DMAC7.html)
WO (1) WO2004065391A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763627B2 (en) * 2003-04-09 2010-07-27 Exelixis, Inc. Tie-2 modulators and methods of use
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
WO2006040966A1 (ja) * 2004-10-08 2006-04-20 Astellas Pharma Inc. 芳香環縮合ピリミジン誘導体
TW200621257A (en) * 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2007117995A2 (en) * 2006-03-30 2007-10-18 Takeda San Diego, Inc. Kinase inhibitors
CN101479274B (zh) 2006-04-26 2013-06-12 霍夫曼-拉罗奇有限公司 药用化合物
WO2007127183A1 (en) 2006-04-26 2007-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
UA95799C2 (en) 2006-04-26 2011-09-12 Ф. Хоффманн-Ля Рош Аг Pharmaceutical compounds
GB0608820D0 (en) * 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
JP2009539988A (ja) * 2006-06-12 2009-11-19 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルの調節因子として有用なチエノピリミジン
CA2671845C (en) * 2006-12-07 2015-03-24 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7888352B2 (en) * 2006-12-07 2011-02-15 Piramed Limited Phosphoinositide 3-kinase inhibitor compounds and methods of use
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US20080260643A1 (en) * 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
JP5658565B2 (ja) * 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
ES2399774T3 (es) * 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
GB0721095D0 (en) 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
US20100093714A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2923734B1 (en) * 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purine analogues and their use as immunosuppressive agents
US8158625B2 (en) * 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
CA2761445A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CN103119047B (zh) 2010-07-23 2016-06-15 哈佛大学校长及研究员协会 三环类蛋白酶体活性增强化合物
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
IN2014CN04558A (cg-RX-API-DMAC7.html) 2011-11-23 2015-09-18 Cancer Rec Tech Ltd
CA2861462A1 (en) * 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity modulating tricyclic compounds
EP2806875B1 (en) * 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
US9758528B2 (en) 2012-09-28 2017-09-12 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017019537A1 (en) 2015-07-24 2017-02-02 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods for treating diseases, and methods for preparing compounds
EP4041739A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
CN115232146A (zh) * 2022-08-04 2022-10-25 山东大学 一种2-氨基噻吩并[2,3-d]嘧啶类化合物及其制备方法和应用
EP4572765A1 (en) 2022-08-18 2025-06-25 Mitodicure GmbH Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728759A1 (en) * 1995-02-24 1996-08-28 Ono Pharmaceutical Co., Ltd. Heterocyclic compounds
US6130223A (en) * 1996-10-24 2000-10-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Thienopyrimidine with phosphodiesterase V inhibiting effect
EP1329454A1 (en) * 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) * 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
JPH1087492A (ja) * 1996-06-25 1998-04-07 Ono Pharmaceut Co Ltd 一酸化窒素産生阻害剤
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
DE19953024A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE19954707A1 (de) 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
MXPA03009925A (es) * 2001-04-30 2004-06-30 Bayer Pharmaceuticals Corp Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas.
EP1348701A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728759A1 (en) * 1995-02-24 1996-08-28 Ono Pharmaceutical Co., Ltd. Heterocyclic compounds
US6130223A (en) * 1996-10-24 2000-10-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Thienopyrimidine with phosphodiesterase V inhibiting effect
EP1329454A1 (en) * 2000-09-29 2003-07-23 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both

Also Published As

Publication number Publication date
US20060229306A1 (en) 2006-10-12
EP1590352A1 (en) 2005-11-02
WO2004065391A1 (en) 2004-08-05
JP2006515604A (ja) 2006-06-01
CN1761671A (zh) 2006-04-19
US7662814B2 (en) 2010-02-16
ATE365742T1 (de) 2007-07-15
ES2289475T3 (es) 2008-02-01
EP1590352B1 (en) 2007-06-27
ES2217956A1 (es) 2004-11-01
DE602004007239D1 (de) 2007-08-09
DE602004007239T2 (de) 2008-02-28
CN100582112C (zh) 2010-01-20

Similar Documents

Publication Publication Date Title
ES2217956B1 (es) Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES2211344B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
CN106879256B (zh) 2-氨基-苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素e合成酶抑制剂的应用
KR20040106536A (ko) Ｐｄｅ４ 저해제로서의 피리다진-３(２ｈ)-온 유도체
CN111712491B (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
AU2019216247B2 (en) Inhibiting the transient receptor potential A1 ion channel
JP2006516653A (ja) キナーゼ阻害剤ピロロトリアジンの製造方法
ES2259891B1 (es) Nuevos derivados de piridotienopirimidina.
ES2259892B1 (es) Nuevos derivados de piridotienopirimidina.
ES2281251B1 (es) Nuevos derivados de pirido (3',2':4,5) furo (3,2-d) pirimidina.
JP3784868B2 (ja) 医薬用水和物

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20041101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2217956B1

Country of ref document: ES

PC2A Transfer of patent
FD1A Patent lapsed

Effective date: 20101018